Company Continues Innovation with a Collaboration with
Yale University to Explore Human Health
Applications and an Expanded Database of Kidney Information
WESTBROOK, Maine, March 26, 2018 /PRNewswire/ -- IDEXX
Laboratories, Inc. (NASDAQ: IDXX) today announced that the IDEXX
Catalyst® SDMA Test is now commercially available to all
United Kingdom and Ireland customers, enabling IDEXX's
point-of-care customers to add SDMA as an essential element of the
routine chemistry panel.
The IDEXX Catalyst® SDMA Test has been in use in
thousands of practices across the United
States and Canada since
December, advancing veterinary healthcare and patient outcomes. The
IDEXX Catalyst® SDMA Test can be added to any chemistry
panel on IDEXX's Catalyst One® and Catalyst
Dx® chemistry analyzers as part of the patient sample
run, with the full chemistry panel results, including SDMA,
available within minutes. There are currently more than 28,000
Catalyst One® and Catalyst Dx® analyzers in
use in veterinary practices worldwide.
Additionally, to further explore SDMA's potential applications
to human health, IDEXX has signed a collaboration agreement with
Yale University. As part of this
partnership with a world-leading human nephrology research
organization, the IDEXX SDMA® Test was validated for
accuracy in measuring SDMA in human blood samples, and the results
were presented at the 2017 annual meeting of the American Society
of Nephrology last November by Yale and
IDEXX researchers. Future research with Yale will focus on the clinical utility of SDMA in
human patients using the validated IDEXX SDMA® Test.
IDEXX first launched the IDEXX SDMA® Test at its
reference laboratories in 2015, and has run more than 14 million
SDMA patient tests, creating the world's largest database on kidney
disease in dogs and cats. The IDEXX SDMA® Test is a
kidney test proven to identify kidney disease earlier than
creatinine,1–3 enabling veterinarians to intervene
earlier to meaningfully impact a patient's health outcomes and
quality of life. Whether the kidney condition is chronic, acute, or
a secondary consequence of other common diseases found in
veterinary medicine, SDMA provides the unique opportunity to gain
important insight into the health of sick or seemingly healthy
patients alike—and take action earlier.
"We've seen great enthusiasm for the ability to run SDMA as part
of the routine chemistry panel at the point of care, and the North
American launch has exceeded our expectations," said Jonathan Ayers, Chairman and Chief Executive
Officer of IDEXX Laboratories. "The IDEXX SDMA Test represents one
of the most significant diagnostic innovations in veterinary
medicine in the last 30 years. We're thrilled to bring this
essential element of the chemistry panel to our point of care IDEXX
VetLab® suite, allowing veterinarians to utilize the
benefits of SDMA immediately during the pet's
appointment."
"SDMA has tremendous potential benefit in human applications as
well," Ayers continued. "And with the IDEXX test technology now
validated to be able to run on commercial chemistry systems that
routinely produce chemistry results in human reference
laboratories, we have greater reason to explore the clinical value
of this incredible biomarker in human applications. We are excited
and grateful for our partnership with Yale
University."
SDMA is the subject of more than 30 ongoing research
collaborations and has been incorporated into the veterinary
profession's International Renal Interest Society (IRIS) kidney
disease staging guidelines. This underscores IDEXX's leadership in
the renal market in the veterinary field and shows that the IDEXX
SDMA® Test is becoming commonly appreciated as an
essential element of the routine chemistry panel.
For more information about the IDEXX Catalyst® SDMA
Test, visit www.idexx.eu/sdma.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a member of the S&P
500® Index and is a leader in pet healthcare innovation,
serving practicing veterinarians around the world with a broad
range of diagnostic and information technology-based products and
services. IDEXX products enhance the ability of veterinarians to
provide advanced medical care, improve staff efficiency and build
more economically successful practices. IDEXX is also a worldwide
leader in providing diagnostic tests and information for livestock
and poultry and tests for the quality and safety of water and milk.
Headquartered in Maine, USA, IDEXX
Laboratories employs more than 7,500 people and offers products to
customers in over 175 countries. For more information about IDEXX,
visit www.idexx.com.
Note Regarding Forward-Looking Statements
This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the use of words
such as "expects," "may," "anticipates," "intends," "would,"
"will," "plans," "believes," "estimates," "should," and similar
words and expressions. These forward-looking statements are based
on management's current expectations and beliefs, as well as a
number of assumptions concerning future events. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the Company's actual results,
performance or achievements to be materially different from those
expressed or implied by these forward-looking statements. IDEXX
assumes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Readers are advised to review IDEXX's filings with the
United States Securities and Exchange Commission (which are
available from the SEC's EDGAR database
at sec.gov and via IDEXX's website
at idexx.com).
References
- Nabity MB, Lees GE, Boggess M, Yerramilli M, Obare E,
Yerramilli M, Rakitin A, Aguiar J, Relford R. Symmetric
dimethylarginine assay validation, stability, and evaluation as a
marker for early detection of chronic kidney disease in dogs. J
Vet Intern Med. 2015;29(4):1036–1044.
- Hall JA, Yerramilli M, Obare E, Yerramilli M, Jewell DE.
Comparison of serum concentrations of symmetric dimethylarginine
and creatinine as kidney function biomarkers in cats with chronic
kidney disease. J Vet Intern Med. 2014;28(6):1676–1683.
- Hall JA, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell
DE. Serum concentrations of symmetric dimethylarginine and
creatinine in dogs with naturally occurring chronic kidney disease.
J Vet Intern Med. 2016;30(3):794–802.
CONTACT:
Media Relations
Robin Woodcock
robin-woodcock@idexx.com
Investor Relations
Kerry Bennett
kerry-bennett@idexx.com
Logo -
https://mma.prnewswire.com/media/155219/idexx_laboratories_logo.jpg